Overview

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Status:
Completed

Trial end date:
2021-02-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation